Home » Newsletters » BioWorld Science

BioWorld Science

May 17, 2011

View Archived Issues

New HIF prolyl hydroxylase inhibitors reported

Serotonin 5-HT4 receptor agonist DA-6886 enhances colonic transit in mice

Merck & Co. reports key developments of first quarter of 2011

DM-CocE protects against and reverses acute cocaine toxicity in rats and primates

Bivalent vaccine CP-5/EPA induces protective antibodies in preclinical studies

Lamellar body mimetic LMS-611 reduces bacterial biofilms in combination with antibiotics

OPC-34712 improves symptoms of depression as adjunctive to standard antidepressant therapy

Anacor Pharmaceuticals present new antiprotozoal agents

Novel gamma-secretase modulators prepared by Pfizer

IntelGenx replies to FDA complete response letter on CPI-300

Tranzyme Pharma discloses new serine protease inhibitors

Prexa Pharmaceuticals raises funds to advance PRX-12251

Merus Labs acquires Vancocin from Iroko Pharmaceuticals

Korean scientists claim new protein kinase inhibitors

Glenmark Pharmaceuticals grants sanofi-aventis license for GBR-500

Swissmedic approves Eisai's Halaven for breast cancer

Teijin Pharma to launch Feburic in Japan for hyperuricemia

CEI to be site for phase I/II MA-09-HRPE trial in Stargardt's macular dystrophy

Merck & Co.'s acquisition of Inspire Pharmaceuticals completed

Ark Therapeutics presents update on drug development pipeline

IDMC recommends continuation of Thallion's phase II trial of ShigamAb

Astellas acquires Perseid Therapeutics from Maxygen

Crizotinib NDA filed in Japan for ALK-positive NSCLC and accepted for priority review in U.S.

UCB profiles events of first quarter 2011

Promising phase II data reported on CT-011 in diffuse large B-cell lymphoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...